Much remains to be solved in lamivudine treatment for HBV-associated liver diseases.
Tanikawa
K
K
D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control / Q000821:virology; D006509:Hepatitis B / Q000188:drug therapy*; D006518:Hepatitis Viruses / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000517:prevention & control / Q000821:virology; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine